NizarM.TannirMD

Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston Deputy Department Chair, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The Univer

Join to view full profile

Dr. Tannir is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Tannir's full profile

Already have an account?

Office
1515 Holcombe Blvd
UT MD Anderson Cancer Center, Unit 1374
Houston, TX 77030
Phone+1 713-792-6161
Is this information wrong?

Education & Training

Muhlenberg Regional Medical CenterResidency, Internal Medicine, 1984 - 1985
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1981 - 1984
American University of Beirut Faculty of MedicineClass of 1979

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 1984 - 2025
OK State Medical License 2020 - 2021
KY State Medical License 1987 - 2015
NJ State Medical License 1985 - 1991
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors:SE Texas Castle Connolly, 2013

Clinical Trials

Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer Start of enrollment: 2007 Mar 01
Completed
Phase 2
Pemetrexed Plus Gemcitabine in Renal Cell Cancer Start of enrollment: 2005 Dec 01
Terminated
Phase 2
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma Start of enrollment: 2007 Jul 01
Completed
Phase 2
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC) Start of enrollment: 2010 May 01
Completed
Phase 1
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma Start of enrollment: 2010 Aug 01
Terminated
Phase 2
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial Start of enrollment: 2011 Jan 19
Active, not recruiting
Phase 2
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) Start of enrollment: 2012 Oct 24
Completed
Phase 2
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma Start of enrollment: 2015 Dec 22
Active, not recruiting
Phase 2
Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer Start of enrollment: 2017 Apr 23
Completed
Phase 1, Phase 2
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma Start of enrollment: 2017 Dec 13
Active, not recruiting
Phase 2
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2018 Aug 17
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

YIA24-001: Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial.
Chad Tang, Kieko Hara, Alexander D Sherry, Alejandra G Serrano, Larisa V Kostousov, Sharia D Hernandez, Wei Lu, Li Shen, Amishi Y Shah, Eric Jonasch, Jose A Karam, Sur...> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.
Sumanta K Pal, Ben Tran, John B A G Haanen, Michael E Hurwitz, Adrian Sacher, Nizar M Tannir, Lihua E Budde, Simon J Harrison, Sebastian Klobuch, Sagar S Patel, Luis M...> ;Cancer Discovery. 2024 Apr 5
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase ...
Robert J Motzer, Toni K Choueiri, Thomas Hutson, Sun Young Rha, Javier Puente, Aly-Khan A Lalani, Eric Winquist, Masatoshi Eto, Naveen S Basappa, Nizar M Tannir, Ulka ...> ;European Urology. 2024 Apr 5
Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma.
Andrew C Johns, Matthew T Campbell, Mamie Gao, Andrew W Hahn, Zita Lim, Emily Wang, Jianjun Gao, Amishi Y Shah, Pavlos Msaouel, Nizar M Tannir> ;The Oncologist. 2024 Mar 13
Radiation Therapy for the Management of Renal Medullary Carcinoma: A Multi-Case Study.
Robert H Mbilinyi, Pavlos Msaouel, Priya Rao, Jose A Karam, Nizar M Tannir, Chad Tang> ;Clinical Genitourinary Cancer. 2024 Mar 5
1 citations
Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.
Andrew W Hahn, Devaki Shilpa Surasi, Paul V Viscuse, Tharakeswara K Bathala, Andrew J Wiele, Matthew T Campbell, Amado J Zurita, Amishi Y Shah, Eric Jonasch, Jianjun G...> ;The Oncologist. 2023 Nov 30
1 citations
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review.
Laurence Albiges, Bradley A McGregor, Daniel Y C Heng, Giuseppe Procopio, Guillermo de Velasco, Naila Taguieva-Pioger, Lidia Martín-Couce, Nizar M Tannir, Thomas Powles> ;Cancer Treatment Reviews. 2024 Jan 1
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract.
Omar Alhalabi, Nathaniel Wilson, Lianchun Xiao, Yiyun Lin, Jaanki Khandelwal, Mohammad Jad Moussa, Pavlos Msaouel, Neema Navai, Jianjun Gao, Ashish M Kamat, Patrick Pi...> ;European Urology Oncology. 2023 Dec 1
Real-World Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma.
Elizabeth Esterberg, Shrividya Iyer, Saurabh P Nagar, Keith L Davis, Nizar M Tannir> ;Clinical Genitourinary Cancer. 2024 Apr 1
1 citations
SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma.
Xian-De Liu, Yan-Ting Zhang, Daniel J McGrail, Xuesong Zhang, Truong Lam, Anh Hoang, Elshad Hasanov, Ganiraju Manyam, Christine B Peterson, Haifeng Zhu, Shwetha V Kuma...> ;Clinical Cancer Research. 2023 Oct 2
2 citations
A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma.
Chijioke Nze, Pavlos Msaouel, Mohamed H Derbala, Bettzy Stephen, Abdulrahman Abonofal, Funda Meric-Bernstam, Nizar M Tannir, Aung Naing> ;Cancers. 2023 Jul 27
4 citations
Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer.
Luigi Perelli, Federica Carbone, Li Zhang, Justin K Huang, Courtney Le, Hania Khan, Francesca Citron, Edoardo Del Poggetto, Tony Gutschner, Hideo Tomihara, Melinda Soe...> ;Nature Cancer. 2023 Jul 1
2 citations
Racial Disparities in MiT Family Translocation Renal Cell Carcinoma.
Xiaofan Lu, Nassim Tawanaie Pour Sedehi, Xiaoping Su, Fangrong Yan, Omar Alhalabi, Nizar M Tannir, Gabriel G Malouf> ;The Oncologist. 2023 Nov 2
6 citations
SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance.
Bujamin H Vokshi, Guillaume Davidson, Nassim Tawanaie Pour Sedehi, Alexandra Helleux, Marc Rippinger, Alexandre R Haller, Justine Gantzer, Jonathan Thouvenin, Philippe...> ;Nature Communications. 2023 May 26
7 citations
Renal Cell Carcinoma of Variant Histology: Biology and Therapies.
Pavlos Msaouel, Giannicola Genovese, Nizar M Tannir> ;Hematology/oncology Clinics of North America. 2023 Oct 1
4 citations
SMARCB1 regulates the hypoxic stress response in sickle cell trait.
Melinda Soeung, Luigi Perelli, Ziheng Chen, Eleonora Dondossola, I-Lin Ho, Federica Carbone, Li Zhang, Hania Khan, Courtney N Le, Cihui Zhu, Michael D Peoples, Ningpin...> ;Proceedings of the National Academy of Sciences of the United States of America. 2023 May 23
3 citations
Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.
Jose A Karam, Pavlos Msaouel, Cara L Haymaker, Surena F Matin, Matthew T Campbell, Amado J Zurita, Amishi Y Shah, Ignacio I Wistuba, Enrica Marmonti, Dzifa Y Duose, Ed...> ;Nature Communications. 2023 May 10
3 citations
Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy.
Daniel D Shapiro, Niki Millward Zacharias, Durga N Tripathi, Menuka Karki, Jean-Philippe Bertocchio, Melinda Soeung, Rong He, Mary E Westerman, Jianjun Gao, Priya Rao,...> ;Clinical and Translational Medicine. 2023 May 1
1 citations
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies.
Omar Alhalabi, Roman Groisberg, Ralph Zinner, Andrew W Hahn, Aung Naing, Shizhen Zhang, Apostolia M Tsimberidou, Jordi Rodon, Siqing Fu, Timothy A Yap, David S Hong, M...> ;NPJ Precision Oncology. 2023 Apr 18
1 citations
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience.
Mirella Nardo, Bulent Yilmaz, Blessie Elizabeth Nelson, Harrys A Torres, Lan Sun Wang, Bruno Palma Granwehr, Juhee Song, Hanna R F Dalla Pria, Van A Trinh, Isabella C ...> ;The Oncologist. 2023 Aug 3
2 citations
Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy.
Andrew W Hahn, Ritesh R Kotecha, Paul V Viscuse, Alberto C Pieretti, Andrew J Wiele, Eric Jonasch, Chung-Han Lee, Jianjun Gao, Amado J Zurita, Amishi Y Shah, Matthew T...> ;European Urology Focus. 2023 Sep 1
1 citations
Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the P...
A S Feils, A K Erbe, J Birstler, K Kim, U Hoch, S L Currie, T Nguyen, D Yu, A O Siefker-Radtke, N Tannir, S M Tolaney, A Diab, P M Sondel> ;Cancer Immunology, Immunotherapy. 2023 Jul 1
4 citations
Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas.
Omar Alhalabi, Jonathan Thouvenin, Sylvie Négrier, Yann-Alexandre Vano, Luca Campedel, Elshad Hasanov, Ziad Bakouny, Andrew W Hahn, Mehmet Asim Bilen, Pavlos Msaouel, ...> ;The Oncologist. 2023 May 8
10 citations
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab.
Jennifer L McQuade, Hans Hammers, Helena Furberg, Andreas Engert, Thierry André, George Blumenschein Jr, Nizar Tannir, Ari Baron, James Larkin, Anthony El-Khoueiry, Da...> ;JAMA Oncology. 2023 Jan 1
18 citations
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
Brian I Rini, Sabina Signoretti, Toni K Choueiri, David F McDermott, Robert J Motzer, Saby George, Thomas Powles, Frede Donskov, Scott S Tykodi, Sumanta K Pal, Saurabh...> ;Journal for Immunotherapy of Cancer. 2022 Dec 1
Join now to see all

Lectures

A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator's choice) in patients with pre...
2019 ASCO Annual Meeting - 6/1/2019
CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

The Latest Breakthroughs That Could Improve Kidney Cancer TreatmentNovember 1st, 2022
MD Anderson Research Highlights: ESMO 2022 Special EditionSeptember 7th, 2022
Mirror Image Molecules Reveal Drought Stress in ForestsSeptember 6th, 2022
Join now to see all